Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Gut Pathogens
Published in: Gut Pathogens 1/2020

Open Access 01-12-2020 | Research

Molecular characteristics of the VP1 region of enterovirus 71 strains in China

Authors: Haiyan Sun, Min Gao, Dawei Cui

Published in: Gut Pathogens | Issue 1/2020

Login to get access

Abstract

Background

Enterovirus 71 (EV71) is the most commonly implicated causative agent of severe outbreaks of paediatric hand, foot, and mouth disease (HFMD).VP1 protein, a capsid protein of EV71, is responsible for the genotype of the virus and is essential for vaccine development and effectiveness. However, the genotypes of EV71 isolates in China are still not completely clear.

Methods

The VP1 gene sequences of 3712 EV71 virus strains from China, excluding repetitive sequences and 30 known EV71 genotypes as reference strains, between 1986 and 2019 were obtained from GenBank. Phylogenetic tree, amino acid homology, genetic variation and genotype analyses of the EV71VP1 protein were performed with MEGA 6.0 software.

Results

The amino acid identity was found to be 88.33%–100% among the 3712 EV71 strains, 93.47%–100% compared with vaccine strain H07, and 93.04%–100% compared with vaccine strains FY7VP5 or FY-23 K-B. Since 2000, the prevalent strains of EV71 were mainly of the C4 genotype. Among these, the C4a subgenotype was predominant, followed by the C4b subgenotype; other subgenotypes appeared sporadically between 2005 and 2018 in mainland China. The B4 genotype was the main genotype in Taiwan, and the epidemic strains were constantly changing. Some amino acid variations in VP1 of EV71 occurred with high frequencies, including A289T (20.99%), H22Q (16.49%), A293S (15.95%), S283T (15.11%), V249I (7.76%), N31D (7.25%), and E98K (6.65%).

Conclusion

The C4 genotype of EV71 in China matches the vaccine and should effectively control EV71. However, the efficacy of the vaccine is partially affected by the continuous change in epidemic strains in Taiwan. These results suggest that the genetic characteristics of the EV71-VP1 region should be continuously monitored, which is critical for epidemic control and vaccine design to prevent EV71 infection in children.
Literature
1.
Yang F, Ren L, Xiong Z, et al. Enterovirus 71 outbreak in the People’s Republic of China in 2008. J ClinMicrobiol. 2009;47(7):2351–2.
2.
Wang Y, Feng Z, Yang Y, et al. Hand, foot, and mouth disease in China: patterns of spread and transmissibility. Epidemiology. 2011;22(6):781–92.PubMedPubMedCentral
3.
Xing W, Liao Q, Viboud C, et al. Hand, foot, and mouth disease in China, 2008–12: an epidemiological study. Lancet Infect Dis. 2014;14(4):308–18.PubMedPubMedCentral
4.
Solomon T, Lewthwaite P, Perera D, et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10(11):778–90.PubMed
5.
Luo Z, Su R, Wang W, et al. EV71 infection induces neurodegeneration via activating TLR7 signaling and IL-6 production. PLoSPathog. 2019;15(11):e1008142.
6.
Antona D, Kossorotoff M, Schuffenecker I, et al. Severe paediatric conditions linked with EV-A71 and EV-D68, France, May to October 2016. Euro Surveill. 2016;21(46):30402.PubMedCentral
7.
Ooi MH, Wong SC, Lewthwaite P, et al. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010;9(11):1097–105.PubMed
8.
Kok CC. Therapeutic and prevention strategies against human enterovirus 71 infection. World J Virol. 2015;4(2):78–95.PubMedPubMedCentral
9.
Ho M, Chen ER, Hsu KH, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med. 1999;341(13):929–35.PubMed
10.
Shih SR, Ho MS, Lin KH, et al. Genetic analysis of enterovirus 71 isolated from fatal and non-fatal cases of hand, foot and mouth disease during an epidemic in Taiwan, 1998. Virus Res. 2000;68(2):127–36.PubMed
11.
Chan KP, Goh KT, Chong CY, et al. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis. 2003;9(1):78–85.PubMedPubMedCentral
12.
Herrero LJ, Lee CS, Hurrelbrink RJ, et al. Molecular epidemiology of enterovirus 71 in peninsular Malaysia, 1997–2000. Arch Virol. 2003;148(7):1369–85.PubMed
13.
Guan D, van der Sanden S, Zeng H, et al. Population dynamics and genetic diversity of C4 strains of human enterovirus 71 in Mainland China, 1998–2010. PLoS ONE. 2012;7(9):e44386.PubMedPubMedCentral
14.
Zhu Z, Zhu S, Guo X, et al. Retrospective seroepidemiology indicated that human enterovirus 71 and coxsackievirus A16 circulated wildly in central and southern China before large-scale outbreaks from 2008. Virol J. 2010;7:300.PubMedPubMedCentral
15.
Wang JR, Tuan YC, Tsai HP, et al. Change of major genotype of enterovirus 71 in outbreaks of hand-foot-and-mouth disease in Taiwan between 1998 and 2000. J Clin Microbiol. 2002;40(1):10–5.PubMedPubMedCentral
16.
Yu H, Chen W, Chang H, et al. Genetic analysis of the VP1 region of enterovirus 71 reveals the emergence of genotype A in central China in 2008. Virus Genes. 2010;41(1):1–4.PubMed
17.
van der Sanden S, van der Avoort H, Lemey P, et al. Evolutionary trajectory of the VP1 gene of human enterovirus 71 genogroup B and C viruses. J GenVirol. 2010;91(Pt 8):1949–58.
18.
Zhang Y, Zhu Z, Yang W, et al. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J. 2010;7:94.PubMedPubMedCentral
19.
20.
Tan X, Huang X, Zhu S, et al. The persistent circulation of enterovirus 71 in People’s Republic of China: causing emerging nationwide epidemics since 2008. PLoS ONE. 2011;6(9):e25662.PubMedPubMedCentral
21.
Tao Z, Wang H, Xu A. Identification of a C2 subgenogroup strain of enterovirus 71 in a retrospective study in Shandong Province, China, from 1990 to 2010. J Clin Microbiol. 2012;50:1823–4.PubMedPubMedCentral
22.
Tao Z, Wang H, Li Y, et al. Molecular epidemiology of human enterovirus associated with aseptic meningitis in Shandong Province, China, 2006–2012. PLoS ONE. 2014;9(2):e89766.PubMedPubMedCentral
23.
Yip CC, Lau SK, Woo PC, et al. Human enterovirus 71 epidemics: what’s next? EmergHealth Threats J. 2013;6:19780.
24.
Chia MY, Chiang PS, Chung WY, et al. Epidemiology of enterovirus 71 infections in Taiwan. PediatrNeonatol. 2014;55(4):243–9.
25.
Huang SW, Cheng HL, Hsieh HY, et al. Mutations in the non-structural protein region contribute to intra-genotypic evolution of enterovirus 71. J Biomed Sci. 2014;21(1):33.PubMedPubMedCentral
26.
Chong P, Liu CC, Chow YH, et al. Review of enterovirus 71 vaccines. Clin Infect Dis. 2015;60(5):797–803.PubMed
27.
Chou AH, Liu CC, Chang JY, et al. Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers. PLoS ONE. 2013;8(11):e79783.PubMedPubMedCentral
28.
Bible JM, Iturriza-Gomara M, Megson B, et al. Molecular epidemiology of human enterovirus 71 in the United Kingdom from 1998 to 2006. J Clin Mocrobiol. 2008;46(10):3192–200.
29.
Huang SC, Hsu YW, Wang HC, et al. Appearance of intratypic recombination of enterovirus 71 in Taiwan from 2002 to 2005. Virus Res. 2008;131(2):250–9.PubMed
30.
van der Sanden S, van Eek J, Martin DP, et al. Detection of recombination breakpoints in the genomes of human enterovirus 71 strains isolated in the Netherlands in epidemic and non-epidemic years, 1963–2010. Infect Genet Evol. 2011;11(5):886–94.PubMed
31.
McWilliam LE, Cabrerizo M, Cardosa J, et al. The association of recombination events in the founding and emergence of subgenogroup evolutionary lineages of human enterovirus 71. J Virol. 2012;86(5):2676–85.
32.
Wen S, Ma D, Lin Y, et al. Complete genome characterization of the 2017 dengue outbreak in Xishuangbanna, a Border City of China, Burma and Laos. Front Cell Infect Microbiol. 2018;8:148.PubMedPubMedCentral
33.
Zhang Y, Tan X, Cui A, et al. Complete genome analysis of the C4 subgenotype strains of enterovirus 71: predominant recombination C4 viruses persistently circulating in China for 14 years. PLoS ONE. 2013;8(2):e56341.PubMedPubMedCentral
34.
Li Y, Zhou Y, Cheng Y, et al. Effectiveness of EV-A71 vaccination in prevention of paediatric hand, foot, and mouth disease associated with EV-A71 virus infection requiring hospitalisation in Henan, China, 2017–18: a test-negative case-control study. Lancet Child Adolesc Health. 2019;3(10):697–704.PubMed
35.
Weng Y, Chen W, Huang M, et al. Epidemiology and etiology of hand, foot, and mouth disease in Fujian province, 2008–2014. Arch Virol. 2017;162(2):535–42.PubMed
36.
Liu Y, Fu C, Wu S, et al. A novel finding for enterovirus virulence from the capsid protein VP1 of EV71 circulating in mainland China. Virus Genes. 2014;48(2):260–72.PubMed
37.
Wu JS, Zhao N, Pan H, et al. Patterns of polymorphism and divergence in the VP1 gene of enterovirus 71 circulating in the Asia-Pacific region between 1994 and 2013. J Virol Methods. 2013;193(2):713–28.PubMed
38.
Zhu H, Cao Y, Su W, et al. Enterovirus A71 VP1 variation A289T decreases the central nervous system infectivity via attenuation of interactions between VP1 and vimentin in vitro and in vivo. Viruses. 2019;11(5):467.PubMedCentral
39.
Nishimura Y, Lee H, Hafenstein S, et al. Enterovirus 71 binding to PSGL-1 on leukocytes: VP1-145 acts as a molecular switch to control receptor interaction. PLoS Pathog. 2013;9(7):e1003511.PubMedPubMedCentral
40.
Chen TC, Liu SC, Huang PN, et al. Antiviral activity of pyridyl imidazolidinones against enterovirus 71 variants. J Biome Sci. 2008;15(3):291–300.
41.
Le TV, Nguyen V, Nguyen QH, et al. Molecular epidemiology analysis of enterovirus 71 strains isolated in Dak Lak, Vietnam, 2011–2016. J Med Virol. 2019;91(1):56–64.PubMed
42.
Zhang B, Wu X, Huang K, et al. The variations of VP1 protein might be associated with nervous system symptoms caused by enterovirus 71 infection. BMC Infect Dis. 2014;14:243.PubMedPubMedCentral
43.
Kobayashi K, Sudaka Y, Takashino A, et al. Amino acid variation at VP1-145 of Enterovirus 71 determines attachment receptor usage and neurovirulence in human scavenger receptor B2 transgenic mice. J Virol. 2018;92(15):e00681–18.PubMedPubMedCentral
44.
Victorio CB, Xu Y, Ng Q, et al. Cooperative effect of the VP1 amino acids 98E, 145A and 169F in the productive infection of mouse cell lines by enterovirus 71 (BS strain). Emerg Microbes Infect. 2016;5(6):e60.PubMedPubMedCentral
45.
Yang CH, Liang CT, Jiang ST, et al. A novel murine model expressing a chimeric mSCARB2/hSCARB2 receptor is highly susceptible to oral infection with clinical isolates of Enterovirus 71. J Virol. 2019;93(11):e00183–19.PubMedPubMedCentral
46.
Zhang H, Song Z, Zou J, et al. An infectious clone of enterovirus 71(EV71) that is capable of infecting neonatal immune competent mice without adaptive mutations. Emerg Microbes Infect. 2020;9(1):427–38.PubMedPubMedCentral
47.
Zhu FC, Meng FY, Li JX, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381(9882):2024–32.PubMed
48.
Mao QY, Wang Y, Bian L, et al. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). Expert Rev Vaccines. 2016;15(5):599–606.PubMed
49.
Yang B, Liu F, Liao Q, et al. Epidemiology of hand, foot and mouth disease in China, 2008 to 2015 prior to theintroduction of EV-A71 vaccine. Euro Surveill. 2017;22(50):16–00824.PubMedCentral
50.
Li R, Liu L, Mo Z, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370(9):829–37.PubMed
51.
Zhu F, Xu W, Xia J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370(9):818–28.PubMed
52.
Hu YM, Wang X, Wang JZ, et al. Immunogenicity, safety, and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months. Clin Vaccine Immunol. 2013;20(12):1805–11.PubMedPubMedCentral
53.
Bessaud M, Razafindratsimandresy R, Nougairede A, et al. Molecular comparison and evolutionary analyses of VP1 nucleotide sequences of new African human enterovirus 71 isolates reveal a wide genetic diversity. PLoS ONE. 2014;9(3):e90624.PubMedPubMedCentral
Metadata
Title
Molecular characteristics of the VP1 region of enterovirus 71 strains in China
Authors
Haiyan Sun
Min Gao
Dawei Cui
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Gut Pathogens / Issue 1/2020
Electronic ISSN: 1757-4749
DOI
https://doi.org/10.1186/s13099-020-00377-2

Other articles of this Issue 1/2020

Gut Pathogens 1/2020 Go to the issue

Review

Gut microbiota changes in children with autism spectrum disorder: a systematic review

Research

Host responses to Clostridium perfringens challenge in a chicken model of chronic stress

Research

Stool cultures show a lack of impact in the management of acute gastroenteritis for hospitalized patients in the Bronx, New York

Research

Distribution of genes related to Type 6 secretion system and lipooligosaccharide that induced ganglioside mimicry among Campylobacter jejuni isolated from human diarrhea in Thailand

Research

Metagenomic analysis of gut microbiome and resistome of diarrheal fecal samples from Kolkata, India, reveals the core and variable microbiota including signatures of microbial dark matter

Short report

Development of a highly effective low-cost vaporized hydrogen peroxide-based method for disinfection of personal protective equipment for their selective reuse during pandemics
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits